Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04875702 · ClinicalTrials.gov registry record · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
A Phase 4 study of Gout, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 650
- Enrollment target
- 7
- Study locations
NCT04875702 is a Phase 4 study of Gout that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 650 participants, below the 8,869-participant average among 34 other Gout trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT04875702, a Phase 4 study of Gout, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 650 participants
- Enrollment target
- 7
- Study locations
Study Summary
The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.
Conditions Studied
Interventions
- DRUG Allopurinol
- DRUG Naproxen 250 MG
- DRUG Colchicine 0.6 mg
- DRUG Colchicine 1.2 mg
- DRUG Naproxen 500 Mg
Study Locations (7)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital (BWH) - Boston
- Boston Medical Center (BMC) - Boston
Alabama
- The University of Alabama at Birmingham - South Birmingham
California
- UCLA Health - Santa Monica
New York
- NYU Langone - New York
West Virginia
- West Virginia University (Including Mobile Clinical Trials Unit) - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04875702
The ClinicalTrials.gov registry entry for NCT04875702 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,869-participant average among 34 other Gout trials with a reported enrollment target (93% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 5 interventions - of which Allopurinol is the first listed.
NCT04875702 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT04875702 about?
NCT04875702 is a clinical study titled "Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout". The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpo...
What is the current status of trial NCT04875702?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 650 participants. The study started on 2024-02-22. Estimated completion is 2028-10-31.
What conditions does trial NCT04875702 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT04875702?
The interventions under investigation include: Allopurinol (DRUG), Naproxen 250 MG (DRUG), Colchicine 0.6 mg (DRUG), Colchicine 1.2 mg (DRUG), Naproxen 500 Mg (DRUG).
Who is sponsoring clinical trial NCT04875702?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04875702 being conducted?
This trial has 7 study locations across Alabama, California, Massachusetts, New York, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares
RECRUITING · Phase 4
-
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
ACTIVE NOT RECRUITING · Phase 4
-
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
COMPLETED · Phase 4
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
RECRUITING · Phase 2
-
A Study of Dotinurad Versus Allopurinol in Participants With Gout
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.